Preclinical studies explained

Präklinische Studien erklärt

Preclinical development is an important part of the drug development process in the pharmaceutical industry. It is the phase before clinical trials in which researchers investigate the safety and efficacy of new medicines. Preclinical studies usually take place in the laboratory and are used to test the potential toxicity, pharmacokinetics and pharmacodynamics of a drug. The preclinical phase of drug development can be divided into two main parts: discovery research and preclinical development. Discovery research involves identifying potential targets and developing lead compounds, while preclinical development focuses on testing these lead compounds to determine if they are safe and effective. In preclinical development, different animal models are used to study the pharmacological effects of a drug. These models help researchers identify possible adverse effects or side effects that may occur in humans. They also help to understand how a drug is metabolised and eliminated from the body.

Pharmacokinetics is the study of how a drug is absorbed, distributed, metabolised and excreted in the body. Pharmacokinetic studies are conducted in preclinical development to determine the optimal dosage and route of administration of a drug. These studies provide important information about the behaviour of a drug in the human body and help researchers develop a dosing regimen that maximises the efficacy of the drug while minimising potential side effects.

Pharmacodynamics is the study of how drugs affect the body. During preclinical development, researchers use various tests to evaluate the pharmacodynamic effects of a drug. These tests measure the activity of the drug at its target site as well as any side effects it may have on other biological pathways. By understanding the pharmacodynamic profile of a drug, researchers can optimise its therapeutic potential and minimise its toxicity potential.

Toxicology is concerned with the effects of drugs on living organisms. During preclinical development, toxicological studies are conducted to assess the safety of a drug. These studies evaluate the toxicity potential of a drug and determine the dose at which toxic effects occur. They also help researchers to identify possible long-term effects that may occur with prolonged use of the drug.

In addition to these preclinical studies, researchers also conduct formulation development and analytical testing during preclinical development. Formulation development is about finding the optimal delivery system for a drug, for example tablets, capsules or injections. Analytical testing is done to ensure that the drug is of high quality and purity, and to determine the stability of the drug over time. The preclinical development phase usually lasts several years and is complemented by clinical trials. Clinical trials are conducted in humans to determine the safety and efficacy of a drug. The data obtained in preclinical development are used to plan these studies and for the regulatory approval process.

In summary, preclinical development is an important part of the drug development process in the pharmaceutical industry. It involves testing the safety and efficacy of new drugs in animal models and evaluating the pharmacokinetics, pharmacodynamics and toxicology of a drug. This information is used to plan clinical trials and for the approval process. Preclinical development usually takes several years and is a necessary step to bring new medicines to market.

Test all the advantages of a digital document management system specially developed for the pharmaceutical and biotech industry now without obligation. You can get started in just five minutes, convince yourself.

Quality management in the pharmaceutical and biotech industry: Current challenges in the cooperation between pharmaceutical companies and CROs, CMOs and CDMOs

"The increasing decentralization of the supply chain in the pharmaceutical industry poses major challenges for companies. In a regulated environment, regulatory requirements must be implemented in a compliant manner while adhering to "Good Documentation Practice" with business partners in a global environment. The global networking and faster availability of information in large numbers are pushing our existing document management systems to their limits in terms of timely processing in compliance with GMP requirements. Therefore, we need to rethink our current way of working to enable effective and efficient document management with new IT solutions."

Timur Güvercinci
Timur Güvercinci